Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
Value in Health - United Kingdom
doi 10.1016/j.jval.2011.07.006
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2011
Authors
Publisher
Elsevier BV